Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$5.5 - $9.19 $81,642 - $136,416
-14,844 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$7.67 - $44.59 $113,853 - $661,893
14,844 New
14,844 $132,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $281M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Nine Point Two Capital LLC Portfolio

Follow Nine Point Two Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nine Point Two Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nine Point Two Capital LLC with notifications on news.